Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. NVDA
2. PSKY
3. META
4. LGND
5. SPY
6. MONC:IM
7. PTON
8. NYXH
9. LXEO
10. MONRY

Go back to Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy
(NASDAQ: XENE) Delayed: 39.01 +0.02 (0.05%)
Previous Close $38.99    52 Week High $9.75 
Open $39.76    52 Week Low $5.65 
Day High $39.76    P/E N/A 
Day Low $38.91    EPS $0.00 
Volume 92,555